Novo Nordisk Teams Up With OpenAI for Drug Discovery

Novo Nordisk has announced a partnership with OpenAI aimed at accelerating drug discovery through artificial intelligence. The collaboration will harness AI to analyze complex datasets and identify promising new treatments. The deal reflects growing optimism in the pharmaceutical industry about AI's potential to transform how new drugs are found and developed. Novo Nordisk joins a wave of major drugmakers exploring AI-driven approaches to speed up and improve the discovery process.